Janux Therapeutics Inc
JANXHealthcare|Biotechnology|USA
$16.41
-0.35 (-2.09%)
DCF (FCF)
$5.59
Tangible Book
$15.47
Upcoming Data Readouts (3)
Oct 2026
Est. completion
Early P1Autoimmune
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
NCT07291323n=60
Jul 2027
Est. completion
P1Prostate Cancer
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449n=272
May 2028
Est. completion
P1Prostate Cancer
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811n=43
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Jul 2026
P1
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622